Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?

Multiple Sclerosis

Volumn 15, Issue 4, 2009, Pages 465-471

  Korteweg, T ^a   Rovaris, M ^b,c   Neacsu, V ^a   Filippi, M ^b,c   Comi, G ^b   Uitdehaag, B M ^a   Knol, D L ^a   Polman, C H ^a   Barkhof, F ^a,c   Vrenken, H ^a   Polman, C ^c   Montalban, X ^c   Rovira, A ^c   Miller, D ^c   Thompson, A ^c   Yousry, T ^c   Fazekas, F ^c   Frederiksen, J ^c   Kappos, L ^c   Palace, J ^c   de Stefano, N ^c   more..

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c NONE

Author keywords

Atrophy; Brain; MRI; Multiple sclerosis; Prediction

Indexed keywords

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS;

ADULT; ATROPHY; BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 63449117773     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508100505     Document Type: Article

References (21)

1. De Stefano, N, Battaglini, M, Smith, S. Measuring brain atrophy in multiple sclerosis. J Neuroimaging 2007; 17(Suppl. 1): 10S-15S.
2. Anderson, V, Fox, N, Miller, D. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. J Magn Reson Imaging 2006; 23: 605-618.
3. Ceccarelli, A, Rocca, M, Falini, A, et al. Normal-appearing white and grey matter damage in MS : A volumetric and diffusion tensor MRI study at 3.0 Tesla. J Neurol 2007; 254: 513-518.
4. Khaleeli, Z, Cercignani, M, Audoin, B, Ciccarelli, O, Miller, D, Thompson, A. Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. Neuroimage 2007; 37: 253-261.
5. Vrenken, H, Geurts, J, Knol, D, et al. Whole-brain T1 mapping in multiple sclerosis: Global changes of normal-appearing gray and white matter. Radiology 2006; 240: 811-820.
6. Poser, C, Brinar, V. Diagnostic criteria for multiple sclerosis. Clin Neurol Neurosurg 2001; 103: 1-11.
7. Comi, G, Filippi, M, Wolinsky, J. European/Canadian multicenter, double-blind, randomized, placebocontrolled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001; 49: 290-297.
8. Rovaris, M, Comi, G, Rocca, M, et al. Long-term follow-up of patients treated with glatiramer acetate: A multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Mult Scler 2007; 13: 502-508.
9. Lublin, F, Reingold, S. Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
10. Smith, S, Jenkinson, M, Woolrich, M, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004; 23(Suppl. 1): S208-S219.
11. Smith, S, Zhang, Y, Jenkinson, M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 2002; 17: 479-489.
12. van Walderveen, M, Barkhof, F, Hommes, O, et al. Correlating MRI and clinical disease activity in multiple sclerosis: Relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. Neurology 1995; 45: 1684-1690.
13. Filippi, M, Rovaris, M, Inglese, M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 1489-1496.
14. Fisher, E, Rudick, R, Simon, J, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-1420.
15. Fox, N, Jenkins, R, Leary, S, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 2000; 54: 807-812.
16. Jasperse, B, Minneboo, A, de Groot, V, et al. Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis. Arch Neurol 2007; 64: 190-194.
17. Kalkers, N, Ameziane, N, Bot, J, Minneboo, A, Polman, C, Barkhof, F. Longitudinal brain volume measurement in multiple sclerosis: Rate of brain atrophy is independent of the disease subtype. Arch Neurol 2002; 59: 1572-1576.
18. Chard, D, Griffin, C, Parker, G, Kapoor, R, Thompson, A, Miller, D. Brain atrophy in clinically early relapsingremitting multiple sclerosis. Brain 2002; 125: 327-337.
19. Dalton, C, Brex, P, Jenkins, R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73: 141-147.
20. Paolillo, A, Pozzilli, C, Giugni, E, et al. A 6-year clinical and MRI follow-up study of patients with relapsingremitting multiple sclerosis treated with Interferon-beta. Eur J Neurol 2002; 9: 645-655.
21. Kalkers, N, Vrenken, H, Uitdehaag, B, Polman, C, Barkhof, F. Brain atrophy in multiple sclerosis: Impact of lesions and of damage of whole brain tissue. Mult Scler 2002; 8: 410-414.